Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 14/20 | 0.56 |
| ▸ | DAGLA | Q9Y4D2 | 7/20 | 0.56 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3959446 | 1.00 | FAAH (0.56) | FAAHDAGLACES1KDM4EALDH1A1 | |
| SCHEMBL3959306 | 1.00 | FAAH (0.56) | FAAHDAGLACES1KDM4EALDH1A1 | |
| SCHEMBL3969330 | 1.00 | FAAH (0.56) | FAAHDAGLACES1KDM4EALDH1A1 | |
| SCHEMBL3966852 | 1.00 | FAAH (0.56) | FAAHDAGLACES1KDM4EALDH1A1 | |
| SCHEMBL3961792 | 1.00 | FAAH (0.56) | FAAHDAGLACES1KDM4EALDH1A1 | |
| SCHEMBL3959024 | 0.99 | FAAH (0.55) | FAAHDAGLACES1KDM4EALDH1A1 | |
| SCHEMBL3963214 | 0.94 | FAAH (0.54) | FAAHDAGLACES1KDM4EALDH1A1 | |
| SCHEMBL3967501 | 0.93 | FAAH (0.66) | FAAHDAGLACES1 | |
| SCHEMBL3963540 | 0.93 | FAAH (0.66) | FAAHDAGLACES1 | |
| SCHEMBL13505064 | 0.90 | FAAH (0.49) | FAAHDAGLACES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270421-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-10-29 | — | — | US | disclosed |
| US-7560570-B2 | Inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-07-14 | — | — | US | disclosed |
| US-20050239785-A1 | Inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-10-27 | — | — | US | disclosed |
| US-6891043-B2 | Inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-05-10 | — | — | US | disclosed |
| US-20030092734-A1 | Inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE | 2003-05-15 | — | — | US | disclosed |
| US-6462054-B1 | ALPHA KETO HETEROCYCLIC PHARMACOPHORE; COMPLEMENTARY BINDING BY ELECTROPHILIC CARBONYL AND WEAKLY BASIC NITROGEN OF SUCH AS OXAZOLOPYRIDINE GROUP; SLEEP AIDS OR ANALGESICS; PRESERVING ENDOGENOUS LEVELS OF OLEAMIDE AND ANANDAMIDE | THE SCRIPPS RESEARCH INSTITUTE | 2002-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270421-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, CNR2 | FAAH 1/4885DAGLA 131/4885CES1 23/4885 |
| US-20030092734-A1 | Inhibitors of fatty acid amide hydrolase | FAAH, FAAH2, CNR2 | FAAH 1/4885DAGLA 202/4885CES1 9/4885 |
| US-20050239785-A1 | Inhibitors of fatty acid amide hydrolase | FAAH, FAAH2, CNR2 | FAAH 1/4885DAGLA 131/4885CES1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.